AB Science will host a reside webcast on its microtubule

PRESS RELEASE

AB SCIENCE WILL HOST A Reside WEBCAST ON ITS MICROTUBULE DESTABILIZER AGENTS (MDA) PLATFORM ON THURSDAY MARCH 1six, 2023, FROM 6PM TO 7PM CET

Paris, 1five March, 202three, 6pm CET

AB Science SA (Euronext – FR0010557264 – AB) will host a reside webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/two with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform.

This reside webcast will present additional specifics on:

• The pharmacological properties of AB8939 and its essential differentiating variables
• The therapeutic possible of AB8939, demonstrated by way of a series of preclinical experiments
• The ongoing Phase 1/two study and the initially case report from the initial stage of this study

The following attendees will participate to the reside webcast:

• Alain Moussy, co-founder and CEO of AB Science
• Olivier Hermine, MD, PhD, Head of the hematological division at the Necker-Enfants Malades hospital, Paris, France
• Christian Auclair, PhD, professional in onco-pharmacology
• Laurent Gros, PhD, Head of Drug Discovery of AB Science

The presentation will be followed by a Q&ampA session with the management of AB Science.

Dial-In &amp Webcast Data

Webcast date: Thursday, March 16, 2023. US: 1pm-2pm ET Europe: 6pm-7pm CET

Dial in numbers to listen the reside webcast:

• Dial in quantity for the US: +1 646 722 4916
• Dial in quantity for France: +33 1 72 72 74 03
• Dial in quantity for nations outdoors US and France: Numbers for other nations are listed on the webcast web page
• Conference ID: 42846282#

Access to the presentation: Access hyperlink to the presentation right here

About AB Science
Founded in 2001, AB Science is a pharmaceutical enterprise specializing in the study, improvement and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are essential in signaling pathways inside cells. Our applications target only ailments with higher unmet health-related requirements, frequently lethal with brief term survival or uncommon or refractory to prior line of therapy.
AB Science has created a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has currently been registered for veterinary medicine and is created in human medicine in oncology, neurological ailments, inflammatory ailments and viral ailments. The enterprise is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Additional data is out there on AB Science’s web page:
www.ab-science.com.

Forward-hunting Statements – AB Science
This press release consists of forward-hunting statements. These statements are not historical details. These statements contain projections and estimates as properly as the assumptions on which they are primarily based, statements primarily based on projects, objectives, intentions and expectations concerning economic benefits, events, operations, future solutions, item improvement and their possible or future overall performance.

These forward-hunting statements can frequently be identified by the words “anticipate”, “anticipate”, “think”, “intend”, “estimate” or “strategy” as properly as other equivalent terms. Although AB Science believes these forward-hunting statements are affordable, investors are cautioned that these forward-hunting statements are topic to a lot of dangers and uncertainties that are tricky to predict and frequently beyond the manage of AB Science and which may perhaps imply that benefits and actual events considerably differ from these expressed, induced or anticipated in the forward-hunting data and statements. These dangers and uncertainties contain the uncertainties associated to item improvement of the Enterprise which may perhaps not be profitable or to the promoting authorizations granted by competent authorities or, a lot more frequently, any variables that may perhaps have an effect on promoting capacity of the goods created by AB Science, as properly as these created or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-hunting data and statements, topic to the applicable regulations, in certain articles 223-1 et seq. of the AMF Basic Regulations.

For further data, please make contact with:

AB Science
Economic Communication &amp Media Relations
investors@ab-science.com